Fig. 2: Synthesis and characterization of LRT nanomedicines. | Nature Communications

Fig. 2: Synthesis and characterization of LRT nanomedicines.

From: Nanomedicine-based co-delivery of a calcium channel inhibitor and a small molecule targeting CD47 for lung cancer immunotherapy

Fig. 2

The representative TEM image of LDH nanosheets (a) and corresponding electron diffraction pattern (b). scale bars: 400 nm, 4/nm. N = 3 samples with similar results. c EDS profile of LDH sample after PEGylation and the elemental analyses by ICP-OES. N = 3 samples with similar results. d Representative Fourier-transform infrared spectra (FT-IR) of LDH before and after PEGylation. N = 3 samples with similar results. e Zeta potential variations in the preparation procedure of LDH nanosheets. The data were expressed as means ± SD (N  =  3 independent experiments). The representative TEM image of LRT nanomedicines (f) and corresponding elemental mappings (g). scale bars: 400 nm. N = 3 samples with similar results. h AFM image of LRT nanosheets. Scale bar, 200 nm. i Powder XRD patterns of LDH nanosheets and LRT nanomedicines. j Release profiles of TTA-Q6 and RRX-001 from LRT in the phosphate buffer saline (pH 6.5 and 7.4). The data were expressed as means ± SD (N  =  3 independent experiments). k Accumulated release profiles of Zn element from LRT in PBS of different pH values. The data were expressed as means ± SD (N  =  3 independent experiments). Source data are provided as a Source Data file.

Back to article page